

- ⁴Continue to look for the underlying cause of events
- ⁵ See Appendix A for Diagnostic Criteria
- ⁶ Long acting insulin should be evaluated and ordered as indicated

Copyright 2024 The University of Texas MD Anderson Cancer Center


Department of Clinical Effectiveness V6 Approved by the Executive Committee of the Medical Staff on 08/20/2024

• Refer to Inpatient Hyperglycemia-Adult algorithm as indicated

HE UNIVERSITY OF TEXAS MDAnderson Cancer Center Making Cancer History[®] Hyperglycemic Emergency Management (DKA/EDKA/HHS) 2-Bag Method - Adult

Page 2 of 11

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care.




Copyright 2024 The University of Texas MD Anderson Cancer Center

THE UNIVERSITY OF TEXAS MDAnderson Cancer Center Making Cancer History[®] Hyperglycemic Emergency Management (DKA/EDKA/HHS) 2-Bag Method - Adult

Page 3 of 11

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care.




¹See Appendix A for Diagnostic Criteria

² If eGFR < 45 mL/minute/1.73 m² or age > 70 years, reduce glargine dose to 0.1 units/kg subcutaneous every 12 hours

THE UNIVERSITY OF TEXAS MDAnderson Cancer Center Making Cancer History[®] Hyperglycemic Emergency Management (DKA/EDKA/HHS) 2-Bag Method - Adult

Page 4 of 11

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care.



¹See Appendix A for Diagnostic Criteria

²Consider reduction for patients with heart failure, end-stage liver or renal disease, or age > 65 years

³Crystalloid IV fluids include 0.9% sodium chloride, plasmalyte, or lactated ringers (see Appendix B)

⁴ For patients with corrected sodium > 147 mmol/L, consider use of 0.45% NS and D5/0.45% NS as base fluids

⁵ For patients with acute kidney injury, eGFR < 45 mL/minute/1.73 m², end stage renal disease, or anuric, consider reducing potassium replacement by 50%

⁶ Refer to the Critical Care Adult PRN Electrolyte Replacement Orders via CVAD, PIV

⁷Consider reducing insulin dose for patients with renal or liver dysfunction/failure

⁸Round infusion dose to nearest 0.1 units/hour

⁹ If eGFR < 45 mL/minute/1.73 m² <u>or</u> age > 70 years, reduce glargine dose to 0.1 units/kg subcutaneous every 12 hours


Department of Clinical Effectiveness V6 Approved by the Executive Committee of the Medical Staff on 08/20/2024

Copyright 2024 The University of Texas MD Anderson Cancer Center

THE UNIVERSITY OF TEXAS MDAnderson Cancer Center Making Cancer History[®] Hyperglycemic Emergency Management (DKA/EDKA/HHS) 2-Bag Method - Adult

Page 5 of 11

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care.



¹ See Appendix A for Diagnostic Criteria

² If eGFR < 45 mL/minute/1.73 m² or age > 70 years, reduce glargine dose to 0.1 units/kg subcutaneous every 12 hours

Cancer Center

Making Cancer History®

THE UNIVERSITY OF TEXAS MDAnderson Hyperglycemic Emergency Management (DKA/EDKA/HHS) 2-Bag Method - Adult

Page 6 of 11

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care.

APPENDIX A: Diagnostic Criteria

	Blood Glucose	pH ¹	Bicarbonate	BHB	Osmolality
DKA	> 250 mg/dL	< 7.3	<15 mEq/L	> 3 mmol/L	< 320 mosm/kg
EDKA	\leq 250 mg/dL	< 7.3	<15 mEq/L	> 3 mmol/L	< 320 mosm/kg
DKA with HHS ²	> 600 mg/dL	< 7.3	<15 mEq/L	> 3 mmol/L	\geq 320 mosm/kg
HHS ² Only	> 600 mg/dL	≥7.3	\geq 15 mEq/L	\leq 3 mmol/L	\geq 320 mosm/kg

¹Arterial or venous

² With marked hypovolemia

Making Cancer History®

Hyperglycemic Emergency Management (DKA/EDKA/HHS) 2-Bag Method - Adult

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care.

APPENDIX B: Crystalloid And Dextrose Containing Fluids

Fluids	Sodium (mEq/L)	Chloride (mEq/L)	Potassium (mEq/L)	Magnesium (mEq/L)	Dextrose (grams/L)	Buffer (mEq/L)	Osmolarity (mOsm/L)	Comments	
Plasma	140	103	4	2	N/A	Bicarbonate (25)	275-290		
0.9% sodium chloride	154	154	N/A	N/A	N/A	N/A	308	Not preferred in patients with/or at risk for hyperchloremia and/or acute kidney injury	
Plasma-Lyte A	140	98	5	3	N/A	Acetate (27)	294	Preferred for patients with low sodium bicarbonate and hyperchloremia. Monitor electrolytes, especially potassium and magnesium	
Lactated Ringers	130	109	4	N/A	N/A	Lactate (28)	273	Contains calcium 3 mEq/L	
D10/0.45% sodium chloride	77	77	N/A	N/A	100	N/A	660		
D10/0.45% with potassium chloride (KCl) 20 mEq ¹	77	77	20	N/A	100	N/A	694	Use in DKA, EDKA, <u>or</u> DKA with HHS	
D5/0.9% sodium chloride	154	154	N/A	N/A	50	N/A	560	Use in HUS Only	
D5/0.9% with potassium chloride (KCl) 20 mEq ¹	154	154	20	N/A	50	N/A	600	Use in HHS Only	
D5/0.45% sodium chloride	77	77	N/A	N/A	50	N/A	406	Use in HHS Only if corrected sodium >	
D5/0.45% with potassium chloride (KCl) 20 mEq ¹	77	77	20	N/A	50	N/A	447	147 mmol/L <u>or</u> in DKA, EDKA, and DKA with HHS only if D10 is unavailable	

¹ Consider potassium containing fluid if potassium level \leq 4.6 mmol/L; adjust potassium content as clinically indicated for renal dysfunction

Copyright 2024 The University of Texas MD Anderson Cancer Center

Department of Clinical Effectiveness V6 Approved by the Executive Committee of the Medical Staff on 08/20/2024

Making Cancer History®

Hyperglycemic Emergency Management (DKA/EDKA/HHS) 2-Bag Method - Adult

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care.

APPENDIX C: DKA, EDKA, or DKA with HHS Blood Glucose Monitoring and Management Using 2-Bag Method

DOC	IV Fluid Titration ¹		IV Insulin Infusion Management ³				
POC Glucose Level	Bag 1 (0.45% NS with or without KCl ²)	% NS with (D10/0.45%NS with • Consider reducing insulin dose for patients with renal or liver dysfunction/failure		Recheck POC Glucose			
In first hour			If glucose does not decrease by at least 75 mg/dL and POC glucose greater than 250 mg/dL, increase IV insulin infusion to 0.15 unit/kg/hour				
> 250 mg/dL	100% hourly IV fluid rate	0% hourly IV fluid rate					
200-250 mg/dL	50% hourly IV fluid rate	50% hourly IV fluid rate	Notify ICU Team if glucose decreases by more than 100 mg/dL/hour for consideration to decrease IV insulin infusion dose by $50\%^3$				
150-199 mg/dL	30% hourly IV fluid rate	70% hourly IV fluid rate					
100-149 mg/dL	10% hourly IV fluid rate	90% hourly IV fluid rate					
70-99 mg/dL	0% hourly IV fluid rate	100% hourly IV fluid rate	 STOP IV INSULIN INFUSION Give D₅₀W 12.5 grams IV push, and notify Endocrinology-General Service and ICU Team Recheck POC glucose every 15 minutes until ≥ 100 mg/dL If POC ≥ 100 mg/dL resume IV insulin infusion at 50% of previous IV insulin infusion dose³ If POC < 100 mg/dL for 2 consecutive checks, notify Endocrinology-General Service and ICU Team for further adjustments³ 	15			
< 70 mg/dL	0% hourly IV fluid rate	100% hourly IV fluid rate	 STOP IV INSULIN INFUSION Give D₅₀W 25 grams IV push, and notify Endocrinology-General Service and ICU Team Recheck POC glucose every 15 minutes until ≥ 100 mg/dL If POC ≥ 100 mg/dL resume IV insulin infusion at 50% of previous IV insulin infusion dose³ If POC < 100 mg/dL for 2 consecutive checks, notify Endocrinology-General Service and ICU Team for further adjustments³ 	15 minutes			

¹Titrate both IV fluids for a combined rate of 100%

² If potassium level \leq 4.6 mmol/L: Add to BOTH bag 1 and 2: potassium chloride (KCl) 20 mEq/L; If potassium level > 4.6 mmol/L: Do NOT add potassium to bag 1 or 2

³ IV insulin infusion dose reduction should only be made twice. Minimal IV insulin infusion dose for DKA, EDKA, <u>or</u> DKA with HHS is 0.025 units/kg/hour.

Copyright 2024 The University of Texas MD Anderson Cancer Center

Making Cancer History®

Hyperglycemic Emergency Management (DKA/EDKA/HHS) 2-Bag Method - Adult

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care.

APPENDIX D: HHS Only Blood Glucose Monitoring and Management Using 2-Bag Method

IV Fluid Titration ¹		IV Insulin Infusion Management ⁴			
Bag 1 (0.9% NS with or without KCl ^{2,3})	Bag 2 (D5/0.9%NS with or without KCl ^{2,3})	 Initiate IV insulin infusion at 0.05 units/kg/hour (maximum initial infusion dose = 15 units/hour) Consider reducing insulin dose for patients with renal or liver dysfunction/failure Round infusion dose to nearest 0.1 units/hour 	Recheck POC Glucose		
		If glucose does not decrease by at least 75 mg/dL and POC glucose greater than 250 mg/dL, increase IV insulin infusion to 0.1 unit/kg/hour	1 hour		
100% hourly IV fluid rate	0% hourly IV fluid rate				
50% hourly IV fluid rate	50% hourly IV fluid rate	Notify ICU Team if glucose decreases by more than 100 mg/dL/hour for consideration to decrease IV insulin infusion	1 hour		
30% hourly IV fluid rate	70% hourly IV fluid rate	dose by $50\%^4$			
10% hourly IV fluid rate	90% hourly IV fluid rate				
0% hourly IV fluid rate	100% hourly IV fluid rate	 STOP IV INSULIN INFUSION Give D₅₀W 25 mL IV push, and notify Endocrinology-General Service and ICU Team Recheck POC glucose every 15 minutes until ≥ 100 mg/dL If POC ≥ 100 mg/dL resume insulin infusion at 50% of previous IV insulin infusion dose⁴ If POC < 100 mg/dL for 2 consecutive checks, notify Endocrinology-General Service and ICU Team for further adjustments⁴ 			
0% hourly IV fluid rate	100% hourly IV fluid rate	 STOP IV INSULIN INFUSION Give D₅₀W 50 mL IV push, and notify Endocrinology-General Service and ICU Team Recheck POC glucose every 15 minutes until ≥ 100 mg/dL If POC ≥ 100 mg/dL resume insulin infusion at 50% of previous IV insulin infusion dose⁴ If POC < 100 mg/dL for 2 consecutive checks, notify Endocrinology-General Service and ICU Team for further adjustments⁴ 	15 minutes		
	Bag 1 (0.9% NS with or without KCl2:3)100% hourly IV fluid rate100% hourly IV fluid rate30% hourly IV fluid rate30% hourly IV fluid rate10% hourly IV fluid rate0% hourly IV fluid rate0% hourly IV fluid rate0% hourly IV fluid rate	Bag 1 (0.9% NS with or without KCl23)Bag 2 (D5/0.9%NS with or without KCl23)100% hourly IV fluid rate0% hourly IV fluid rate100% hourly IV fluid rate0% hourly S0% hourly IV fluid rate30% hourly IV fluid rate70% hourly IV fluid rate30% hourly IV fluid rate70% hourly IV fluid rate10% hourly IV fluid rate90% hourly IV fluid rate0% hourly IV fluid rate100% hourly IV fluid rate0% hourly IV fluid rate100% hourly IV fluid rate0% hourly IV fluid rate100% hourly IV fluid rate0% hourly 	Bag 1 $(0.9\% NS with orwithout KCl2-3)Bag 2(D5/0.9%NS with orwithout KCl2-3)• Initiate IV insulin infusion at 0.05 units/kg/hour (maximum initial infusion dose = 15 units/hour)• Consider reducing insulin dose for patients with renal or liver dysfunction/failure• Round infusion dose to nearest 0.1 units/hour100% hourlyIV fluid rate0% hourlyIV fluid rateIf glucose does not decrease by at least 75 mg/dL and POC glucose greater than 250 mg/dL, increase IV insulininfusion to 0.1 unit/kg/hour100% hourlyIV fluid rate0% hourlyIV fluid rateNotify ICU Team if glucose decreases by more than 100 mg/dL/hour for consideration to decrease IV insulininfusiondose by 50%410% hourlyIV fluid rate100% hourlyIV fluid rateNotify ICU Team if glucose decreases by more than 100 mg/dL/hour for consideration to decrease IV insulininfusiondose by 50%40% hourlyIV fluid rate100% hourlyIV fluid rateSTOP IV INSULIN INFUSION• Give Ds_0W 25 mL IV push, and notify Endocrinology-General Service and ICU Team• If POC > 100 mg/dL• If POC > 100 mg/dL for 2 consecutive checks, notify Endocrinology-General Service and ICU Team for furtheradjustments40% hourlyIV fluid rate100% hourlyIV fluid rate• STOP IV INSULIN INFUSION• Give Ds_0W 25 mL IV push, and notify Endocrinology-General Service and ICU Team for furtheradjustments40% hourlyIV fluid rate100 mg/dLI POC > 100 mg/dL resume insulin infusion at 50% of previous IV insulin infusion dose4• STOP IV INSULIN INFUSION• Give Ds_0W 50 mL IV push, and notify Endocrinology-General Service and ICU Team• Recheck POC glucose every 15 minutes until \geq 100 mg/dL• If POC > 100 mg/dL resume insulin infusion at 50% of p$		

² If potassium level \leq 4.6 mmol/L: Add to BOTH bag 1 and 2: potassium chloride (KCl) 20 mEq/L;

If potassium level > 4.6 mmol/L: Do NOT add potassium to bag 1 or 2

Copyright 2024 The University of Texas MD Anderson Cancer Center

⁴ Insulin infusion dose reduction should only be made one time. Minimal insulin infusion dose for HHS Only is 0.025 units/hour. Department of Clinical Effectiveness V6

Approved by the Executive Committee of the Medical Staff on 08/20/2024

MDAnderson Cancer Center

Making Cancer History®

n Hyperglycemic Emergency Management ^{er} (DKA/EDKA/HHS) 2-Bag Method - Adult

Page 10 of 11

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care.

SUGGESTED READINGS

- De Beer, K., Michael, S., Thacker, M., Wynne, E., Pattni, C., Gomm, M., . . . Ullah, K. (2008). Diabetic ketoacidosis and hyperglycaemic hyperosmolar syndrome-clinical guidelines. *Nursing in Critical Care, 13*(1), 5-11. https://doi.org/10.1111/j.1478-5153.2007.00259.x
- El Sayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., . . . Gabbay, R. A. (2023). 16. Diabetes care in the hospital: Standards of care in diabetes-2023. *Diabetes Care, 46*(Suppl 1), S267-S278. https://doi.org/10.2337/dc23-S016
- Honarmand, K., Sirimaturos, M., Hirshberg, E. L., Bircher, N. G., Agus, M. S. D., Carpenter, D. L., . . . Jacobi, J. (2024). Society of Critical Care Medicine guidelines on glycemic control for critically ill children and adults 2024. *Critical Care Medicine, 52*(4), e161-e181. https://doi.org/10.1097/CCM.00000000006174
- Joint British Diabetes Societies for Inpatient Care. (2023). *The management of diabetic ketoacidosis in adults*. Retrieved from https://abcd.care/sites/default/files/site_uploads/JBDS_Guidelines_Current/JBDS_02_DKA_Guideline_with_QR_code_March_2023.pdf
- Kitabchi, A. E., Umpierrez, G. E., Fisher, J. N., Murphy, M. B., & Stentz, F. B. (2008). Thirty years of personal experience in hyperglycemic crises: Diabetic ketoacidosis and hyperglycemic hyperosmolar state. *The Journal of Clinical Endocrinology & Metabolism, 93*(5), 1541-1552. https://doi.org/10.1210/jc.2007-2577
- MD Anderson Institutional Policy Attachment #ATT3663 Managing Patients with Insulin Pumps
- MD Anderson Institutional Policy Attachment #ATT3587 Guidelines for Patients with a Continuous Glucose Monitor (CGM)
- Mustafa, O. G., Haq, M., Dashora, U., Castro, E., . . . Dhatariya, K. K.(2023). Management of hyperosmolar hyperglycaemic state (HHS) in adults: An updated guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care Group. *Diabetic Medicine*, 40(3), e15005. https://doi.org/10.1111/dme.15005
- Peters, A. L., Buschur, E. O., Buse, J. B., Cohan, P., Diner, J. C., & Hirsch, I. B. (2015). Euglycemic diabetic ketoacidosis: A potential complication of treatment with sodium-glucose cotransporter 2 inhibition. *Diabetes Care*, *38*(9), 1687-1693. https://doi.org/10.2337/dc15-0843
- Plewa, M. C., Bryant, M., & King-Thiele, R. (Eds.). (2021). Euglycemic diabetic ketoacidosis. StatPearls [Internet]. StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK554570/
- Rosenstock, J. & Ferrannini, E. (2015). Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. *Diabetes Care, 38*(9), 1638-1642. https://doi.org/10.2337/dc15-1380
- Self, W. H., Evans, C. S., Jenkins, C. A., Brown, R. M., Casey, J. D., Collins, S. P., . . . Semler, M. W. (2020). Clinical effects of balanced crystalloids vs saline in adults with diabetic ketoacidosis: A subgroup analysis of cluster randomized clinical trials. *JAMA Network Open*, *3*(11), e2024596. https://doi.org/10.1001/jamanetworkopen.2020.24596
- Umpierrez, G. E., Davis, G. M., ElSayed, N. A., Fadini, G. P., Galindo, R. J., Hirsch, I. B., . . . Dhatariya, K. K. (2024). Hyperglycaemic crises in adults with diabetes: A consensus report. *Diabetologia*, 10.1007/s00125-024-06183-8. Advance online publication. https://doi.org/10.1007/s00125-024-06183-8

Making Cancer History®

Hyperglycemic Emergency Management (DKA/EDKA/HHS) 2-Bag Method - Adult

Page 11 of 11

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care.

DEVELOPMENT CREDITS

This practice consensus statement is based on majority opinion of the Hyperglycemic Emergency Management workgroup at the University of Texas MD Anderson Cancer Center for the patient population. These experts included:

Core Development Team Leads

Joshua Botdorf, DO (Critical Care Medicine) Michelle Horng, PharmD (Pharmacy Clinical Programs) Victor Lavis, MD (Endocrine Neoplasia and HD) Sonali Thosani, MD (Endocrine Neoplasia and HD)

Workgroup Members

Karen Chen, MD (Critical Care Medicine) Wendy Garcia, BS[•] Tami Johnson, PharmD (Pharmacy Clinical Programs) Judd Melancon, MSN, APRN (Critical Care Medicine) Mary Lou Warren, DNP, APRN, CNS-CC[•] Courtney Wilkes, BSN, RN (Nursing ICU)

* Clinical Effectiveness Development Team